Not on air · 2 of 3 networks checked
APLUSA
- aplusaresearch.com
- Healthcare & Life Sciences
- FR
- 253 employees
APLUSA’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 22. Watch APLUSA with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| None recorded | 0 | Checked 30 Oct 2026 | See all 22 ads → | ||
| Meta | Not checked | — | |||
| Recently | 4 | Ads on the Google Ads Transparency Center | Checked 4 Oct 2026 | Collect them with the API → |
APLUSA has no live LinkedIn ads. We recorded 4 Google ads on 4 Oct 2026.
Latest ads
- LINKEDIN · ARTICLESince 16 Oct 2026
COPD biologics have demonstrated clinical efficacy. But how do we bridge the gap between eligible patients and real-world treatment? For pharma teams, the challenge goes beyond clinical evidence: understanding patient profiles, eligibility criteria, and the barriers shaping treatment decisions. Explore our latest analysis, featuring insights from APLUSA Therapy Intelligence.
- LINKEDIN · VIDEOSince 6 Oct 2026
#MultipleMyeloma | CAR-T, bispecifics, ADCs: where do they fit in the evolving multiple myeloma treatment pathway? Dr Nicolas Blin explores how hematologists are navigating increasingly complex sequencing decisions, from choosing between CAR-T and bispecifics to considering T-cell fitness earlier in the treatment journey. As new therapies move into earlier lines, the question is no longer just which treatment to use, but when. 🎙️ Watch the full interview: https://lnkd.in/efcypNXQ/?utm_campaign=Boost-MMPodcastOct20262/4&utm_source=linkedin&utm_medium=paid&utm_id=1228134703&hsa_acc=507818082&hsa_cam=1228134703&hsa_grp=895902863&hsa_ad=1572787193&hsa_net=linkedin&hsa_ver=3
- LINKEDIN · IMAGESince 5 Oct 2026
Where will your next strategic answer come from? Explore a new market, understand prescribing dynamics, or answer a specific business question — with decision-ready data already available, no new custom study required. Therapy Intelligence™ by APLUSA | Ready now | 2026 budget, 2027 value
- LINKEDIN · IMAGESince 5 Oct 2026
Where will the next wave of GLP-1 growth come from? Understand who starts, stays, switches, stops — or never begins — and what drives these decisions across 4,000+ consumers in 6 markets. Weight Health Therapy Intelligence™ | Results early November | Secure your scope before October 30.
- LINKEDIN · IMAGESince 5 Oct 2026
Where will the next wave of GLP-1 growth come from? Understand who starts, stays, switches, stops — or never begins — and what drives these decisions across 4,000+ consumers in 6 markets. Weight Health Therapy Intelligence™ | Results early November | Secure your scope before October 30.
- LINKEDIN · IMAGESince 5 Oct 2026
Where will your next strategic answer come from? Explore a new market, understand prescribing dynamics, or answer a specific business question — with decision-ready data already available, no new custom study required. Therapy Intelligence™ by APLUSA | Ready now | 2026 budget, 2027 value
6 of 22 adsSign up to see every APLUSA ad, filter by format and date, and get alerts on new ones.
See all 22 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.